| Literature DB >> 29622976 |
Yasser Yazied Abdelmonem1, Adel Abdelgawad Bakr1, Hossam Ghanem El-Hossary1, Mohammed Mahmoud Abdel Ghany1.
Abstract
BACKGROUND: The characterization of patients who have acute myocardial infarction (AMI) and insignificant coronary stenosis is unclear. AIM: The present study aimed to investigate the clinical profile, in-hospital and 3-month outcome of AMI patients with insignificant coronary stenosis in comparison with those with significant disease.Entities:
Keywords: Acute myocardial infarction; Insignificant coronary artery disease; Prognosis
Year: 2017 PMID: 29622976 PMCID: PMC5883485 DOI: 10.1016/j.ehj.2017.03.001
Source DB: PubMed Journal: Egypt Heart J ISSN: 1110-2608
Demographics and clinical characteristics between non-significant (Group I) and significant (Group II) CAD.
| Variable | Group I (n = 100) | Group II (n = 100) | p-value |
|---|---|---|---|
| Age, yr | 56 (50.0–61.5) | 65 (59.0–71.0) | < |
| Age < 55 yr | 44 (44.0%) | 21 (21.0%) | |
| Female Gender | 41 (41.0%) | 23 (23.0%) | |
| Non-white race | 51 (51.0%) | 36 (36.0%) | |
| BMI > 30 kg/m2 | 4 (4.0%) | 6 (6.0%) | 0.516 |
| Current smoking | 29 (29.0%) | 48 (48.0%) | |
| History of substance abuse | 4 (4.0%) | 1 (1.0%) | 0.369 |
| History of CAD | 9 (9.0%) | 19 (19.0%) | |
| History of PCI | 4 (4.0%) | 11 (11.0%) | |
| History of heart failure | 6 (6.0%) | 8 (8.0%) | 0.579 |
| Anti-ischemic therapy | 9 (9.0%) | 18 (18.0%) | 0.063 |
| Family history of CAD | 16 (16.0%) | 12 (12.0%) | 0.415 |
| Type II DM | 36 (36.0%) | 61 (61.0%) | < |
| Hypertension | 52 (52.0%) | 50 (50.0%) | 0.777 |
| Dyslipidemia | 45 (45.0%) | 49 (49.0%) | 0.571 |
| Renal insufficiency | 4 (4.0%) | 5 (5.0%) | 1.000 |
| Peripheral vascular disease | 0 (0.0%) | 2 (2.0%) | 0.497 |
| History of stroke | 0 (0.0%) | 2 (2.0%) | 0.497 |
Data are presented as median (interquartile range) or number (%).
Results of quantitative laboratory work-up across groups.
| Variable | Group I (n = 100) | Group II (n = 100) | p-value | |
|---|---|---|---|---|
| Peak troponin I, ng/ml | 0.0005 (0–0.74) | 53.5 (17.5–80.5) | < | |
| Peak CKMB, ng/ml | 4.1 (3.2–5.05) | 116.5 (67–218.5) | < | |
| Total cholesterol, mg/dl | 177 (144–244) | 188.5 (132–298) | 0.089 | |
| LDL, mg/dl | 134.5 (123–186.5) | 143.5(119.5–250) | ||
| HDL, mg/dl | 42.5 (37–49) | 41.5 (31–53) | ||
| TG, mg/dl | 132 (115–192) | 135.5 (114–218) | 0.053 | |
| WBC, 1,000/mm3 | 7.4 (6.5–8.3) | 8.2 (7.1–9.6) | 0.086 | |
| Hematocrit,% | 47.9 (46.7–49.4) | 48.3 (46.9–50.0) | 0.230 | |
| Blood sugar, mg/dl | 124 (112.5–255) | 126.5 (113–293.5) | 0.109 | |
| HbA1c, % | 6.8 (4.9–8.7) | 7.1 (5.2 –9.1) | 0.123 | |
| Serum creatinine on | ||||
| Admission mg/dl | 0.9 (0.8–1.1) | 0.98 (0.89–1.1) | 0.098 | |
Data are presented as median (interquartile range).
Medications received during hospital stay across groups.
| Medication | Group (n = 100) | Group II (n = 100) | p-value |
|---|---|---|---|
| Nitroglycerin | 59 (59.0%) | 79 (79.0%) | |
| Beta-blockers | 66 (66.0%) | 85 (85.0%) | |
| CCB | 20 (20.0%) | 3 (3.0%) | < |
| ACEI/ARB | 43 (43.0%) | 62 (62.0%) | |
| Diuretics | 9 (9.0%) | 10 (10.0%) | 0.809 |
| GPIIb/GPIIIa inhibitors | 0 (0.0%) | 4 (4.0%) | 0.121 |
Data are presented as number (%).
Medications prescribed on discharge across groups.
| Medication | Group I (n = 100) | Group II (n = 100) | p-value |
|---|---|---|---|
| Beta-blockers | 52 (52.0%) | 85 (85.0%) | < |
| CCB | 20 (20.0%) | 3 (3.0%) | < |
| ACEI/ARB | 43 (43.0%) | 65 (65.0%) | |
| Diuretics | 9 (9.0%) | 10 (10.0%) | 0.809 |
Data are presented as number (%).
In-hospital clinical outcome across groups.
| Outcome | Group I (n = 100) | Group II (n = 100) | p-value |
|---|---|---|---|
| Recurrent angina | 0 (0.0%) | 6 (6.0%) | |
| CHF | 7 (7.0%) | 7 (7.0%) | 1.000 |
| Cardiogenic shock | 0 (0.0%) | 6 (6.0%) | |
| Mechanical complications | 0 (0.0%) | 1 (1.0%) | 1.000 |
| Sustained VT | 1 (1.0%) | 4 (4.0%) | 0.369 |
| Stroke/TIA | 0 (0.0%) | 0 (0.0%) | - |
| In-hospital Mortality | 0 (0.0%) | 1 (1.0%) | 1.000 |
Data are presented as number (%).
Outcome after 3 month follow-up across groups.
| Outcome | Group I (n = 100) | Group II (n = 100) | p-value |
|---|---|---|---|
| Readmission for ACS | 1 (1.0%) | 9 (9.0%) | |
| Need for revascularization | 1 (1.0%) | 8 (8.0%) | |
| Cardiac mortality | 0 (0.0%) | 1 (1.0%) | 1.000 |
Data are presented as number (%).
Multivariable binary logistic regression analysis for prediction of insignificant CAD.
| 95% CI for Exp (B) | ||||||
|---|---|---|---|---|---|---|
| Variable retained in the model | B | SE | Sig. | Exp (B) | Lower | Upper |
| Age < 55 yr | 0.91 | 0.53 | 2.49 | 0.89 | 6.98 | |
| Female gender | 1.85 | 0.56 | 6.39 | 2.15 | 18.99 | |
| Non-white race | 1.00 | 0.48 | 2.71 | 1.05 | 6.98 | |
| Non-smoker | 1.51 | 0.52 | 4.52 | 1.62 | 12.64 | |
| No hypertension | −1.58 | 0.58 | 0.21 | 0.07 | 0.64 | |
| No dyslipidemia | −1.16 | 0.57 | 0.31 | 0.10 | 0.96 | |
| No family history of CAD | −2.35 | 0.80 | 0.10 | 0.02 | 0.46 | |
| A typical chest pain | 2.04 | 0.68 | 7.68 | 2.01 | 29.39 | |
| Lower CK-MB | 3.17 | 0.62 | < | 23.77 | 7.12 | 79.36 |
| Constant | −2.58 | 1.17 | 0.08 | |||
| Hosmer & Lemeshow test | p-value, 0.938 | |||||
| Accuracy | 86% | |||||
| Area under the ROC curve (AUC) | 0.939 (95% CI, 0.908–0.970; | |||||
| Youden index J | 0.74 | |||||
| Associated criterion (probability) | >0.66 | |||||
| Sensitivity | 82% | |||||
| Specificity | 92% | |||||
Predictors of insignificant CAD.
| Variables | p-value |
|---|---|
| Young age < 55 years | p < 0.001 |
| Female | p = 0.006 |
| Non-white | p = 0.032 |
| No current/recent smoker | p = 0.006 |
| Absence of DM | p < 0.001 |
| No Prior CAD | p = 0.042 |
| No Prior PCI | p = 0.037 |
| A typical chest pain | p < 0.001 |
| Lower elevation in peak troponin I level | p < 0.001 |
| Lower elevation in peak CK-MB level | p < 0.001 |
| Lower LDL-C level | p = 0.006 |
| Higher HDL-C level | p = 0.020 |
| No ST-segment changes on presentation | p < 0.001 |
| Preserved left ventricular (LV) function | p < 0.0001 |